Tag: Business Wire

• Brightseed Bio 01™ is the first ingredient in Brightseed’s portfolio of bioactives discovered by its artificial intelligence (A.I.) platform Forager®
• Formulated to optimize bioactives that support gut health, Brightseed Bio 01™ is a new dietary fiber ingredient for the food and beverage industry
• Brightseed Bio 01™ will debut at SupplySide West 2022 and be featured in a newly developed protein crisp from plant-based food pioneer, Puris

SAN FRANCISCO–(BUSINESS WIRE)–Brightseed, the bioactive discovery company, announced today the launch of Brightseed Bio 01™, a novel dietary hemp fiber to support gut health formulated for use in food and beverages. Sourced from upcycled hemp hulls and formulated to optimize bioactive content, Brightseed Bio 01™ is the only dietary fiber on the market that contains two bioactive compounds that have shown the ability to support gut barrier integrity in preclinical studies.

Brightseed Bio 01™ will debut at SupplySide West (SSW), held October 31 – November 4, 2022 in Las Vegas (booth #2075). Brightseed’s new ingredient will be showcased in a number of on-trend prototypes, including a first-to-market protein crisp ingredient, BioCrisp+, jointly developed by Brightseed and Puris, a leading supplier of plant-based proteins, starches and grains.

“We’re thrilled to launch Brightseed Bio 01™, the first of many bioactive ingredients in Brightseed’s pipeline that will enable companies to innovate for health and bring science-backed solutions forward for consumers,” said Sofia Elizondo, co-founder and COO, Brightseed. “More than ever, people are turning to the food and beverage industry for proactive and personalized health solutions. Brightseed Bio 01™ is the latest demonstration of how Forager® A.I. is furthering our understanding of how bioactives found in nature are powerful catalysts to improve human healthspan.”

Dietary fiber is an essential part of any healthy diet because of its ability to help maintain normal gut health. But today, only 5% of Americans consume the recommended daily intake. Brightseed Bio 01™ infuses food and beverage products with a unique combination of both dietary fiber and bioactives to support gut strength.

The gut health benefits that distinguish Brightseed Bio 01™ were identified by Brightseed’s A.I. platform Forager®. Brightseed Bio 01™ contains two naturally occurring plant compounds, N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT), that help maintain gut barrier integrity, according to Brightseed’s recently presented preclinical research.¹ Clinical research studies are underway to validate this health effect. Forager® also identified hemp hulls as the richest known source of NCT and NFT. Hemp hulls are a rich source of dietary fiber that are largely a byproduct of hemp heart production, which Brightseed has upcycled to create Brightseed Bio 01.™ In addition, Brightseed Bio1™ offers a high concentration of dietary fiber, enabling manufacturers to easily achieve a good source of fiber content in their products.

Formulated to optimize bioactive content to support overall gut health, Brightseed Bio 01™ can be easily integrated into cereals, granolas, nutrition bars and functional beverages, among other popular items. Brightseed will demonstrate their fiber’s unique attributes in several product prototypes at SSW, including the newly formulated Puris BioCrisp+ made with Brightseed Bio 01™. The crisp is designed for inclusion in cereals, bars and baked goods, where it will deliver delicious, nutrition-packed crunch with an excellent source of protein and good source of fiber.

“Sustainability and innovation are the core of what we do at PURIS. Partnering with Brightseed on a crisp that revitalizes a fiber stream to create a complete plant protein encompasses what we see as the future of the plant-based space,” said Tyler Lorenzen, CEO, PURIS Proteins.

Anna Gustafson, RDN and Business Development Executive at PURIS added, “Bioactives have been missing from American diets, and attention to their functions is the future of better-for-you products. PURIS is excited to partner with Brightseed on a novel protein crisp that targets the fiber deficit and rising consumer demand for gut health solutions.”

“Puris is an ideal partner that is at the forefront of plant-based, sustainability-focused health innovation that solves challenges food companies face, and we’re thrilled to debut Brightseed Bio 01™ with them in a revolutionary protein crisp for immediate consumer product integration,” said Alina Slotnik, VP of Bioactives, Brightseed. “Brightseed Bio 01™ not only demonstrates how Forager® is rapidly translating insights into tangible products for the marketplace but offers a true evolution in the field of nutrition science to benefit consumer health.”

For more about Brightseed Bio 01™, visit booth #2075 at SupplySide West 2022, October 31-November 4, or https://www.brightseedbio.com/bioactives

1. Bolster, Doug. “Impact of two novel plant bioactives on rescue of impaired gut barrier function using human primary cell intestinal epithelium.” Presented at International Society for Nutraceuticals and Functional Foods Annual Conference, October 2-5, 2022. https://isnffweb.meetinghand.net/projectData/921/webData/Program-Book.pdf

About Bioactives

Bioactives are small molecule compounds produced by plants, fungi, and microbes that grow in and adapt to environments that present a wide range of challenges to their survival. Bioactives also benefit the health of humans – they are the enlivening caffeine in tea, the powerful antioxidant lycopene in tomatoes or curcumin in turmeric, and they inform active ingredients in medicines like Taxol, aspirin and Metformin, the latter a first-line treatment for Type 2 diabetes derived from the French lilac flower. Science has long known that bioactives are critical to human health, yet the vast majority remain unknown and uncharted – often referred to as the “dark matter” of nutrition. Brightseed’s A.I., Forager®, discovers bioactives in nature and maps them to human health outcomes at a rate and accuracy that was previously impossible.

About Brightseed

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Visit www.brightseedbio.com to learn more.

About PURIS

PURIS is the leading supplier of pea protein in North America. The family-owned company is leading the plant-based protein movement by making organic and non-GMO ingredients more functional, accessible, affordable, and nutrient-rich. PURIS develops the ingredients that fuel retail’s biggest brands, from alternative meats to non-dairy milks and everything in between. The company’s domestic end-to-end system ensures a wholesome journey from seed to solution. PURIS was recently named the most innovative food company in the world. Visit www.puris.com to learn more.

Contacts

Serene Buckley

Brightseed

press@brightseedbio.com

Lauren Perez

PURIS

lperez@purisfoods.com

LAS VEGAS–(BUSINESS WIRE)–Flower One Holdings Inc. (“Flower One” or the “Canadian Company”) (CSE: FONE) (FSE: F11), the Canadian parent company of the leading cannabis cultivator and producer in Nevada, announces that the Supreme Court of British Columbia (the “Court”) has, among other things, extended the stay period in the Company’s Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) proceeding commenced by each of the Canadian Company and its Canadian subsidiaries Flower One Corp. and FO Labour Management Ltd. (collectively, the “Canadian Companies”), to January 16, 2023 (the “Stay Extension”). The Canadian Company also announces that on October 25, 2022, it obtained an order (the “Claims Process Order”) establishing a claims process (the “Claims Process”) to identify and determine claims against the Canadian Companies.

The Stay Extension and the Claims Process will allow the Canadian Company to develop and pursue a sale and/or plan of arrangement that would have the effect of restructuring the Canadian Companies’ balance sheets, and facilitate the injection of additional capital, with a view of Flower One’s business going private as soon as reasonably practicable, thereby eliminating the administrative burden and significant expense associated with being a publicly listed company. During this time, the US operations of Flower One are expected to continue in the ordinary course and without interruption.

Pursuant to the Claims Process Order, the Canadian Companies will send a claims notice (the “Claims Notice”) to each known creditor of the Canadian Companies, which will set out the claim such creditor has against each of the Canadian Companies, according to the records of the Canadian Companies. If a creditor agrees with its claim as set out in the Claims Notice, no further action is required. Any creditor that (i) disputes the claim set forth in the Claims Notice; (ii) wishes to assert a claim against any director or officer of the Canadian Companies; (iii) wishes to assert a restructuring claim; or (iv) does not receive a Claims Notice but wishes to assert a claim against any of the Canadian Companies or any of their directors or officers, must submit a proof of claim with the Monitor (defined below) by no later than 4:00 p.m. (PST) on Monday November 14, 2022 or the Restructuring Claims Bar Date (as defined in the Claims Process Order), all in accordance with the terms of the Claims Process Order. A copy of the Claims Process Order, along with all schedules attached thereto, can be found at the Monitor’s website listed below.

As previously reported, PricewaterhouseCoopers Inc. has been appointed to act as the Canadian Companies’ monitor under the CCAA (in such capacity, the “Monitor”). Further information regarding the Claims Process and copies of the documents and forms referenced therein are available at the Monitor’s website at www.pwc.com/ca/FONE. Further information regarding the CCAA proceedings can be obtained by contacting the Monitor via email at ca_flowerone@pwc.com.

About Flower One Holdings Inc.

Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket’s, HUXTON, and Flower One’s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for top-performing brands in cannabis. Flower One’s Nevada footprint includes its flagship facility, a 400,000 square-foot high-tech greenhouse and 55,000 square-foot production facility, as well as a second site with a 25,000 square-foot indoor cultivation facility and commercial kitchen. Flower One has built an industry-leading team focused on making high-quality cannabis accessible to all.

The Canadian Company’s common shares are traded on the Canadian Securities Exchange under the Canadian Company’s symbol “FONE”, and on the Frankfurt Stock Exchange under the symbol “F11”. For more information, visit: https://flowerone.com.

Cautionary Note Regarding Forward-Looking Information

Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of United States securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Canadian Company to be materially different from historical results or from any future actual results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or other similar expressions to be uncertain and forward-looking.

Forward-looking statements may include, without limitation, statements relating to the Claims Process and Claims Notice, the expected outcome, timing and completion of the balance sheet restructuring and CCAA proceedings, including expectations with respect to the injection of additional capital; risks related to the CCAA proceedings and the impact of same on Flower One’s operations; expectations that the US operations of Flower One will continue in the ordinary course and without interruption; the expected outcome, timing and completion of Flower One going private, including obtaining required approvals; the timing of posting of updates, materials and/or information on the Canadian restructuring process; Flower One’s position as a leader in the Nevada cannabis market; Flower One’s leadership as a cannabis cultivator, producer, innovator and full-service brand fulfillment partner; and the production of a wide range of products for the nation’s top-performing brands.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the “Cautionary Statement regarding Forward-Looking Information” section contained the Canadian Company’s management’s discussion and analysis for the three and six month periods ended June 30, 2022 (the “MD&A”). All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Canadian Company’s public securities filings with the Canadian securities commissions, including the Canadian Company’s MD&A. Although Flower One has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended.

Although Flower One believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this press release are made as of the date of this release. Flower One disclaims and does not undertake any intention or obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contacts

Flower One Investor Relations

ir@flowerone.com

Kellen O’Keefe, President & CEO

702.660.7775

Flower One Media

media@flowerone.com

As company announces exciting plans to expand medical marijuana business and enter adult use market, workers will enjoy important union protections, trainings and benefits.

WEST BERLIN, N.J.–(BUSINESS WIRE)–United Food and Commercial Workers (UFCW) Local 360 is pleased to announce the decision by workers at Harmony Foundation, and its Harmony Dispensary in Secaucus, NJ., to unionize as members of UFCW. Harmony employees can now add their names to the quickly growing ranks of UFCW Local 360 from across New Jersey’s young marijuana economy. Recently, Harmony announced its intention to expand into the adult use marijuana market, and to open locations in Hoboken, Jersey City – as well as a new cultivation site in Lafayette.

“It’s great news for these workers, and their families. They carefully considered, and then selected, the career-supporting benefits that come with joining Local 360,” said Hugh Giordano, UFCW Local 360’s director of organizing. “From making sure that sick and suffering patients get the help they need, to educating them on how to properly experience the benefits of medical marijuana and supporting the expansion of this industry, they’ve shown their commitment to the promise of the cannabis economy.”

“Across the cannabis industry, a new generation of workers is discovering that bona fide labor unions play a critical role in properly balancing the needs of employees, communities and employers,” said Sam Ferraino, Jr., UFCW Local 360 president. “This vote is not just a show of support in the promise of unions to positively impact businesses, families and communities, it’s also a declaration in support of high operating standards and a diverse and skilled workforce with good working conditions.”

“We’ve always said that UFCW supports cannabis industry workers from seed to sale,” added Giordano. “And with a company like Harmony, that’s clearly the case. They’re already a name in medical marijuana, with their own cultivation and dispensary operations, and they’re actively looking to expand, both geographically through new stores and by entering the adult use market. It’s the right time to join with Local 360, and we’re proud that these workers came to the same conclusion.”

From seed to sale, UFCW is a recognized leader in organizing cannabis industry employees and is the official AFL-CIO designated cannabis labor union. Representing tens of thousands of cannabis workers in dispensaries, labs, delivery, manufacturing, processing, grow facilities and more, UFCW works with employees and business owners to achieve the shared goal of a regulated cannabis industry that delivers family-sustaining jobs and is focused on social equity.

About United Food and Commercial Workers: The UFCW International Union represents over 1.3 million hardworking families across the U.S. and Canada. These members work in essential industries such as Retail, Warehousing, Manufacturing, Healthcare, Transportation, the Public Sector and Cannabis.

Contacts

Hugh Giordano,

UFCW 360 Director of Organizing,

609-367-5594

hgiordano@ufcw360.org

Berkshire Roots will add a “Cookies Corner” in Pittsfield and will retail Cookies’ products in its Boston location

PITTSFIELD, Mass. & BOSTON–(BUSINESS WIRE)–Berkshire Roots today announced a partnership with international cannabis brand Cookies to add the Cookies Corner concept inside its flagship medical and adult-use dispensary in Pittsfield, Massachusetts. Through its partnership with Cookies, Berkshire Roots will expand the options available to people who are local to Pittsfield and to those who visit The Berkshires on vacation, visiting one of the many art, music or theater venues or have second homes in the area. Berkshire Roots is already well-known as an award-wining cultivator and manufacturer as well as earning the Berkshire Eagles’ “Best of The Berkshires” award four years in a row. In addition, Berkshire Roots’ East Boston location, also an award-winning destination, will carry Cookies products and accessories.

“Berkshire Roots is continuously looking for the best-of-the best to offer our customers,” stated Berkshire Roots CEO, James Winokur. “While we create exceptional products, customers do ask us about carrying other brands and product styles. Cookies is the brand we are asked about the most, so being selected as the exclusive authorized retailer in The Berkshires is a great honor for us and will be greatly appreciated by our customers.”

Customers in The Berkshires and Boston will have access to a wide menu of popular Cookies strains as well as Lemonnade, Minntz and Collins Ave brands available in Massachusetts. Berkshire Roots will also carry a selection of Cookies SF branded accessories and gear which will be available at both retail locations.

“When we consider which retailers will carry our Cookies products and become a Cookies Corner, we look for retail operators that have a proven track record in their local market. Berkshire Roots is that partner for us in Pittsfield, Massachusetts, and we are excited to open a Cookies Corner with them,” said Parker Berling, President of Cookies.

The Cookies Corner opened officially on October 24th at the Berkshire Roots Pittsfield, MA cannabis campus. Stop by Halloweed Weekend and check out the Corner, located at 501 Dalton Avenue, Pittsfield, MA. Cookies strains and some accessories will also be available at 253 Meridian Street, East Boston, MA minutes from Logan Airport. To learn more, please visit BerkshireRoots.com

About Cookies

Cookies, founded in 2010 by Billboard-charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai, is the most globally recognized cannabis company in the world. Cookies values the power of the plant and focuses on creating game-changing genetics. The company offers a collection of over 70 proprietary cannabis cultivars and more than 2,000 products. Cookies also actively works to enrich communities disproportionately impacted by the War on Drugs through advocacy and social equity initiatives. Headquartered in San Francisco, the company opened its first retail store in 2018 in Los Angeles, and has since expanded to over 50 retail locations in 17 markets across 5 countries. Cookies was named one of America’s Hottest Brands of 2021 by AdAge; the first cannabis brand to ever receive this accolade. To learn more about Cookies, visit cookies.co, and to learn more about Cookies CBD, visit shop.cookies.co/

About Berkshire Roots

Berkshire Roots is one of Massachusetts leading cannabis cultivation and dispensary operators providing craft-grown cannabis from Berkshire County, the highest elevation in the state. The company’s team members in cultivation, extraction lab and infused products are considered amongst the best in the state. Strict quality control and lab testing ensure patients and consumers experience the ultimate cannabis experience no matter the product type. Berkshire Roots branded products are sold in its own dispensaries and throughout dispensaries around the state.

Berkshire Roots is committed to using our voice to end racial injustice within our community and at the national level through its diversity training, hiring practices and donations to related organizations. Learn more at BerkshireRoots.com

Contacts

press@berkshireroots.com

DUBLIN–(BUSINESS WIRE)–The “Global Medical Marijuana Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.

The medical marijuana market is poised to grow by $14.47 bn during 2022-2026, accelerating at a CAGR of 18.91% during the forecast period. The report on the medical marijuana market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising number of product launches, an increasing number of medical marijuana dispensaries, and plans to increase the production and availability of medical marijuana by governments.

The medical marijuana market analysis includes the application segment and geographic landscape.

The medical marijuana market is segmented as below:

By Application

• Chronic pain
• Nausea
• Others

By Geographical Landscape

• North America
• Europe
• APAC
• South America
• Middle East and Africa

This study identifies the increasing number of awareness campaigns as one of the prime reasons driving the medical marijuana market growth during the next few years. Also, the launch of medical marijuana education programs and an increase in funding for research and production of medical marijuana will lead to sizable demand in the market.

The report on the medical marijuana market covers the following areas:

• Medical marijuana market sizing
• Medical marijuana market forecast
• Medical marijuana market industry analysis

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

Companies Mentioned

• Aphria Inc
• Aurora Cannabis Inc.
• Cannabis Sativa Inc
• Canopy Growth Corp.
• Cronos Group Inc
• CV Sciences Inc.
• Emerald health therapeutics inc
• Etain LLC
• HEXO Corp
• Isodiol International Inc.
• Jazz Pharmaceuticals Plc
• Khiron Life Sciences Corp
• Maricann Group Inc
• Medical Marijuana Inc
• Organigram Holdings Inc
• Phoena Holdings Inc
• Tikun Olam Ltd
• Tilray Inc
• Trevena Inc
• VIVO Cannabis Inc

For more information about this report visit https://www.researchandmarkets.com/r/9ay1lt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Employees at the company’s Edgewater, New Jersey dispensary, which serves both medical marijuana and adult use customers, are among the latest to join UFCW.

WEST BERLIN, N.J.–(BUSINESS WIRE)–United Food and Commercial Workers (UFCW) union, Local 360, announces that employees at Curaleaf’s Edgewater, NJ., dispensary have voted to organize as members of UFCW. The Curaleaf location in Edgewater originally served only medical marijuana patients, but now also serves the adult use market. Nationally, Curaleaf operates 134 local dispensaries and 26 cultivation sites across 22 states.

“Votes like this will keep New Jersey’s cannabis economy thriving for years to come. A whole new generation of workers is discovering that labor unions play a critical role in balancing the needs of employees, communities and employers, and they want in,” said Hugh Giordano, UFCW Local 360 director of organizing. “And when we take the recent decision to pardon people convicted of ‘simple possession’ into account, it’s clear that the mission of protecting cannabis workers in their workplaces, and establishing a fair and equitable industry that supports family-sustaining jobs, is making serious progress.”

Curaleaf describes itself as a company of leaders, community members and responsible employers. With the decision by its Edgewater location to join with UFCW Local 360, those claims are made even stronger and more tangible, according to Giordano.

“Wherever cannabis is legalized, UFCW is committed to building a successful, responsible industry,” said Sam Ferraino, Jr., UFCW Local 360’s president. “Every vote to unionize is workers saying they want to be part of something special and they are in it for the long-haul. The most successful employers will be those that hear this message and embrace its implications.”

From seed to sale, UFCW is a recognized leader in organizing cannabis industry employees and is the official AFL-CIO designated cannabis labor union. UFCW represents tens of thousands of cannabis workers across the US in dispensaries, labs, delivery, kitchens, manufacturing, processing, grow facilities and more. It works with employees and business owners to achieve the shared goals of creating a regulated cannabis industry that delivers family-sustaining jobs and is focused on social equity.

About United Food and Commercial Workers: The UFCW International Union represents over 1.3 million hardworking families across the U.S. and Canada. These members work in essential industries such as Retail, Warehousing, Manufacturing, Healthcare, Transportation, the Public Sector and Cannabis.

Contacts

Media:
Hugh Giordano,

Director of Organizing,

609-680-5718

hgiordano@ufcw360.org

Disruptive Cloud-Hosted Subscription-Based Ad Management Solution Delivers 48% Higher Return on Google Ad Spend (ROAS)

SAN ANTONIO–(BUSINESS WIRE)–AiAdvertising, Inc. (OTC: AIAD), a next-generation AdTech company focused on harnessing the power of artificial intelligence (AI) and machine learning (ML) to build software for today’s marketing leaders, announced it has achieved early success with BioHarvest Sciences’ (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) first commercialized blood flow superfood supplement VINIA.

BioHarvest, a plant cell growth company, became the first and only company that grows cells of plants at industrial scale in liquid bioreactors in order to produce the secondary metabolites. In April 2022, they partnered with AiAdvertising for its resveratrol superfood supplement VINIA® for its Google related search advertising. Initial results were very positive and by mid-August 2022, VINIA had seen over 180% increase in revenue from their Google spend and a 48% higher Return on Ad Spend (ROAS). AI Advertising played a critical role in scaling BioHarvest’s Google platform advertising. As a result of AI systems, the increase in ROAS by 48% allowed BioHarvest to double their media spend on Google.

Based on this superior performance, AiAdvertising has now been engaged to enhance BioHarvest’s major U.S. marketing scale-up, which has added National Television. As of September 30, 2022, AiAds has seen further improved results, and BioHarvest’s overall Return on Ad Spend since April 2022 increased by 90%. AiAds’ management of Google advertising is a foundational component in BioHarvest’s overall marketing mix which includes TV, Radio, and other online channels.

“We are impressed with the results of our collaboration with AiAdvertising, one of our key strategic ecommerce partners,” stated Ilan Sobel, CEO of BioHarvest Sciences. “Artificial Intelligence is now permeating every business sector imaginable and the commercial applications we are beginning to see in digital Advertising simply cannot be ignored. Our partnership with AiAdvertising, while still in its infancy, played a critical role as a key member of our ecosystem of marketing partners in scaling our VINIA business and delivering a step-change in our revenue performance and in the improvement of key metrics such as ROAS. We look forward to building on the great momentum and leveraging more of the AI Platform, not only for VINIA®, but also for our future pipeline of products.”

VINIA employs AiAdvertising’s Campaign Performance Platform (CPP), which is the industry’s first cloud-hosted subscription-based Ad Management solution that enables brands and agencies to easily plan, create, predict, execute, scale, and measure digital advertising campaigns.

“These initial outcomes with VINIA have led to a month-over-month increase in BioHarvest’s budget and has helped drive triple digit revenue growth for VINIA sales in the third quarter,” said Jerry Hug, CEO of AiAdvertising. “We are seeing similar results across our client base, and it is now clear the momentum with our disruptive Campaign Performance Platform is gaining traction as we are leveraging AI in our platform to drive performance. We look forward to executing on the next phase of our campaign with BioHarvest as they bring their lead product VINIA to consumers in need of a superior heart healthy blood flow supplement.”

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

About AiAdvertising

AiAdvertising, Inc. (OTC: AIAD) is a next-generation AdTech company that is harnessing the power of artificial intelligence (AI) and machine learning (ML) to build software for today’s marketing leaders. We are focused on eliminating waste and maximizing the return on digital ad spend.

Our flagship product, the Campaign Performance Platform, is a subscription-based, end-to-end Ad Management solution. The platform empowers brands and agencies to easily target, predict, create, scale, and measure hyper-personalized campaigns.

For more information about the Company, please visit www.AiAdvertising.com or our LinkedIn or Twitter pages.

Forward-Looking Statements

This press release may contain “forward-looking statements.” Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements are included in our filings with the Securities and Exchange Commission, including the “Risk Factors” section of our annual report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as may be required under applicable law.

Contacts

Investor Contact:
Larry Holub/Chris Tyson

312-261-6412

AIAD@mzgroup.us
www.mzgroup.us

Press Contact:
Kati Waldenburg/Joe McGurk

973-924-9797

AIADPR@mzgroup.us

The event brings more than 100 current and aspiring East Coast-based budtenders together for networking opportunities and a deep-dive into the science and history of cannabis

SEATTLE–(BUSINESS WIRE)–Today, Leafly Holdings, Inc. (“Leafly”), a leading cannabis discovery marketplace and resource, celebrates the 2nd Annual International Budtender Day with an exclusive networking and training event in Hoboken, NJ for current and aspiring budtenders – frontline cannabis retail workers – from new and up-and-coming East Coast. The event is in partnership with Business of Cannabis, a company that specializes in highlighting the companies, brands, people and trends driving the cannabis industry in North America.

The only holiday that recognizes the often unrecognized workers in cannabis, Leafly’s International Budtenders Day celebrates the budtenders’ role in empowering customers with the knowledge they need to discover the benefits of cannabis, bringing awareness to an often overlooked profession that plays a crucial role in the success of the cannabis industry.

During the event, Leafly will announce the two winners of a nationwide contest the company ran this month to recognize those who epitomize the ideal budtender:

• Mandi Drake, Verilife in Liverpool, NY
• Jacquelyn McTighe, Youngtown Curaleaf in Youngtown, Arizona

Budtenders are the face of the cannabis industry. They are expected to understand cannabis and have the customer service skills necessary to explain the complexities of cannabis to a curious public. The position requires a passion for cannabis, exceptional knowledge of cannabis products and their effects, and strong customer service skills. As New York, Vermont, Connecticut, Rhode Island, and New Jersey continue to open their adult-use cannabis stores, demand for budtenders is rising across the East Coast.

“The cannabis industry will never be as small as it is now and the demand for experienced budtenders will continue to grow. It is so rare to have an opportunity to shape an industry from its inception and this is an exciting time for new budtenders,” said Dr. Nick Jikomes, Leafly’s Director of Science and Innovation. “Leafly is the informed way to shop for weed and we believe knowledge is power. There is no better way to celebrate this holiday than by sharing information about this magical plant with up and coming budtenders seeking to join this emerging field.”

Leafly offers budtenders cannabis online educational opportunities at no cost with thousands of educational articles covering every topic relevant to the industry. Two formal Leafly Learn courses are also available to budtenders employed by Leafly-subscribed retailers. Since launching the Leafly Learn platform in 2019, more than 13,000 budtenders from North America have enrolled in the program.

The event in Hoboken – offered at no cost on a first come, first serve basis – features two training sessions led by Leafly experts:

• What Are Cannabis Strains? A chemistry-first approach on how different strains provide different effects.
• Three Ways to Shop for Weed: a deep-dive into cannabinoids, terpenes, and through a hands-on “terp bar”

Members of the press in the New York City area are invited to attend the event upon request.

About Leafly

Leafly helps millions of people discover cannabis each year. Our powerful tools help shoppers make informed purchasing decisions and empower cannabis businesses to attract and retain loyal customers through advertising and technology services. Learn more at Leafly.com or download the Leafly mobile app through Apple’s App Store or Google Play.

Contacts

Callie Driehorst

Callie.Driehorst@leafly.com

KFAR SAVA, Israel–(BUSINESS WIRE)–MediCane Health Inc. (along with its subsidiaries together referred to as “MediCane”) today announced the recruitment of the first patient for its clinical study designed to achieve relief of agitation and disruptive behaviors in subjects with probable Alzheimer’s disease (AD) who do not respond or only partially respond to treatment with antipsychotic medications.

The trial is being conducted in two leading academic hospitals in Israel, Sheba Medical Center and Sourasky Medical Center. A total of 55 subjects will receive MediCane’s balanced T3:C3 oral medical cannabis oil extracted from MediCane’s proprietary strain and formulated for blinding purposes, on top of standard of care. Part one of the study is an open-label phase that will enroll 15 subjects for safety and dose-range finding; Part two is a randomized, double-blind, placebo-controlled phase that will enroll 40 subjects to evaluate safety and efficacy.

The study is co-funded by Dr. Reddy’s Laboratories, a leading multinational pharmaceutical company, which holds exclusive sales and marketing rights for the product in Europe (except CIS countries).

“MediCane is proud to collaborate with two of the leading medical centers in Israel in our journey to find a safe and effective cannabis-based medicine for BPSD symptom relief,” said Dr. Nurit Tweezer-Zaks, Chief Executive Officer of MediCane R&D. “Through this joint effort and with the active collaboration of Dr. Reddy’s Laboratories we hope to be able to successfully complete the study during 2024 and launch the product in Israel, Germany and additional EU markets.”

“The mission of MediCane Health Inc. is to develop evidence-based treatments created from cannabis plants in its derived molecules. We see symptom reduction as a clinically meaningful goal of the cannabis plant for BPSD,” said Dr. Neta Rimmerman, VP MediCane R&D. “Based on our proprietary strain cultivated in Israel, we developed an oil-based formulation that showed promising results in pre-clinical research.”

Alzheimer’s disease is a chronic neurodegenerative disease that accounts for most dementia cases worldwide. Dementia is a syndrome in which there is deterioration in memory, thinking, behavior, and the ability to perform everyday activities. Among the Behavioral and Psychological Symptoms of Dementia (BPSD), agitation and disruptive behaviors, expressed as excessive fidgeting, restlessness, pacing, shouting, screaming, uninhibited behaviors, and aggression, are present in over half of patients with dementia at some point during the illness. This syndrome has significant negative consequences on the patient’s life and the lives of those around him, and it causes severe dependence on others and considerable fatigue on the main caregiver.

“The toolbox available to the treating physicians today to deal with BPSD symptoms is very limited,” according to Co-Principal Investigator Professor Ramit Ravona-Springer, Director of the Psychogeriatric and Memory Clinic at the Sheba Medical Center. “Our goal is to add cannabis-based treatments to the existing treatment arsenal to achieve symptom relief in a non-sedative manner which will provide caregivers with the opportunity to continue effective home care to their loved ones. My team and I are excited to lead this innovative clinical trial for the benefit of patients in Israel and around the world.”

“Me and my team are delighted to join the critical mission of helping dementia patients and their families,” said Co-Principal Investigator Dr. Noa Bergman, Director of the Memory and Attention Disorders Center, Neurology Department at the Sourasky Medical Center. “The balancing act of the available treatment options is very challenging as the risks might often outweigh the benefits. We witness the suffering of the patients and caregivers daily and are committed to collaborate with MediCane Health to find alternative cannabis-based solutions relying on robust clinical evidence.”

About MediCane’s balanced T3:C3 oil

MediCane’s balanced T3:C3 oil is an oral medical cannabis oil extracted from MediCane’s proprietary strain in GMP-grade olive oil, which is based on a marketed balanced T3:C3 (THC:CBD) MediCane product. During the clinical trial, MediCane’s balanced T3:C3 is administered sublingually using a dropper, three times a day, following a designated titration protocol.

About MediCane Health Inc.

MediCane Health Inc. is a fully integrated International Medical Cannabis Company. Its subsidiaries M.H MediCane Ltd. And MediCane R&D Ltd. develop both Medical Cannabis, as well as pharmaceutical products derived from synthetic and isolated cannabis molecules, in three therapeutic areas: Dementia, Insomnia, and IBS (irritable bowel syndrome). MediCane’s R&D activities are carried out in-house by its experienced team and through collaboration with world-renowned scientists and leading research institutions, which provide the analytical, biological, and medical expertise. Using a patient-centric approach to clinical trials, MediCane aims to provide potent cannabis-based pharmaceutical products to treat inflammatory and neurological diseases.

For more information please visit: https://medicane.net

Contacts

+972 (0)74 769 5959

info@medicane.net
www.medicane.net

Clinical study demonstrates significant improvement in pain

LONDON–(BUSINESS WIRE)–Curaleaf International (the “Company”) part of Curaleaf Holdings (CNSX:CURA), Europe’s largest vertically integrated cannabis company, is pleased to announce that Chief Scientific Officer, Dr Barbara Pacchetti will present research on one clinical study and three preclinical studies at a leading conference on medical cannabis on 21-22 October 2022. These papers have been peer-reviewed and selected for presentation and publication in the official Conference Proceedings Journal Medical Cannabis and Cannabinoids (Karger Publishers, Basel, Switzerland).

Research to be presented from the clinical study focuses on the delivery of a cannabidiol (CBD) preparation to patients with Vestibulodynia (VBD) which is a prevalent form of chronic genital pain in women with no standard treatment. The study, a randomized placebo control study, of 60 patients showed significant improvement of outcomes on pain, dyspareunia (genital pain before, during or after sex), pelvic muscular tone and neurometer parameters, which highlights implications for its anti-inflammatory, anti-nociceptive action and anti-neuropathic therapeutic potential. The title of the paper is: Transmucosal delivery of cannabidiol using vestibular electroporation in patients with vestibulodynia: interim analysis of a randomized, blinded prospective trial. The co-authors are F. Murina, Prof. MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.

Preclinical research to be presented focuses on the potential positive impact of CBD on the treatment of several psychiatric disorders and inflammatory disease, the therapeutic potential for migraine pain and trigeminal excitability related to migraine. For further information on the preclinical research to be presented, please see the footnote at the end of this announcement.*

Dr. Barbara Pacchetti, Chief Scientific Officer at Curaleaf International, commented, “We are very pleased with the findings from our clinical study on the delivery of CBD to treat patients with VBD, and that it is showing a significant improvement in pain outcomes for patients. Additionally, the preclinical research on the therapeutic potential of CBD to treat a number of other indications is also encouraging and I look forward to presenting this to the scientific community and to furthering our research into the potential for CBD. We believe the growth and understanding of medical cannabis must be underpinned by the most robust science. Curaleaf International is working with some of the world’s leading academic institutions such as Imperial College, the University of Milan and University of Insubria and we look forward to further updating all stakeholders with our progress.”

To learn more about the conference please visit the conference website.

About Curaleaf International

Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021.

For more information about Curaleaf International, please visit:

https://www.curaleafinternational.com/

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, and Grassroots provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 21 states with 144 dispensaries, 26 cultivation sites, and employs over 6,000 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

*Details on the preclinical studies

Cannabidiol (CBD) is considered a valuable potential treatment for several psychiatric disorders. This preclinical study demonstrates, for the first time, that CBD is detected in the plasma and medial prefrontal cortex (mPFC), following single or repeated treatment at therapeutical doses, with a specific dose-response profile. CBD significantly modulates brain-derived neurotrophic factor (BDNF) expression, a neurotrophin critical for synaptic plasticity, following a brain specific anatomical pattern. This modulatory effect on BDNF might be functionally relevant and represent added value for the potential therapeutic role of CBD in psychiatric disorders.

(Title and Authors: Cannabidiol exposure modulated the BDNF system in the rat cortico-striatal circuitry – F. Mottarlini, M. Fumagalli, F. Castillo-Diaz, S. Piazza, G. Targa, E. Sangiovanni, B. Pacchetti, M.H. Sodergren, M. Dell’Agli, F. Fumagalli and L. Caffino)

Polymorphonuclear leukocytes (PMN) are the first immune cell to be recruited into inflammatory sites, and cannabidiol (CBD) extensively affects their functions. This study confirmed the anti-inflammatory activity of CBD on some PMN functions observed in a previous study. Results indicate that CBD counteracts the effects of priming on key functions such as migration and ROS production, strengthening its therapeutic potential in inflammatory disease.

(Title and Authors: Effects of cannabidiol on migration and reactive oxygen species production in bacterial lipopolysaccharide primed human polymorphonuclear leukocyte – F. Marino, E. Rasini, A. Luini, M. Legnaro, A. Gemma, B. Pacchetti, M. H. Sodergren, M. Cosentino)

Clinical and preclinical data have suggested a deregulation of the endocannabinoid system (ECS) in migraine pain and trigeminal excitability related to migraine. This in-vivo study evaluated and found key information on the accumulation of Cannabidiol (CBD) in brain areas that are involved in migraine pain in an animal model at therapeutical doses chronically, and evidenced that a single CBD administration may reduce trigeminal hyperalgesia in an animal model for migraine pain. The results suggested the capability of CBD to modulate migraine-related nociceptive transmission via specific central and peripheral regions.

(Title and Authors: Cannabidiol as a potential treatment for migraine: preliminary data in an animal model. R Greco, C Demartini, M Francavilla, M Palmisani, A M Zanaboni, R Marchiselli, S Facchetti, V Franco, B Pacchetti, C Tassorelli)

CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

Contacts

Media enquiries:
Buchanan
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz

Tel: +44 (0) 20 7466 5000

curaleafint@buchanan.uk.com
www.buchanan.uk.com